Navigation Links
Generex Provides Further Information for March 30 Press Conference & Investor Call to Discuss Management's Strategic Development Plan for Future Growth
Date:3/24/2011

rties currently held by the Company for the benefit of its stockholders.

In addition, Generex will host an investor call to discuss this plan along with the current status of its various clinical and regulatory initiatives on March 30, 2011 at 4:30 p.m. ET.   The details for participating in the investor call are as follows:

Participant Operator-Assisted Toll-Free Dial-in Number:877.303.7204Participant Operator-Assisted International Dial-in Number:224.357.2384About Generex Biotechnology Corporation Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Generex Schedules Press Conference & Investor Call for March 30th to Discuss Managements Strategic Development Plan for Future Growth
2. Generex Announces New Treatment IND Site for the USFDA Expanded Access Treatment IND Program for Generex Oral-lyn™ in the United States
3. Generex Oncology Receives New Patent for AE37 Immunotherapeutic Cancer Vaccine
4. Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study
5. Generex and RXi Pharmaceuticals Announce Positive Research Data Using RNAi Technology in the Development of Therapeutic Vaccines for Cancer
6. Generex Announces Extension of Global Medical Direct Acquisition Closing Date
7. Generex Receives New Patent for Buccal Drug Delivery Platform Technologies
8. Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal
9. Generex Oncology Awarded Two IRS Therapeutic Discovery Project Grants
10. Generex Common Stock Now Quoted on the Over-the-Counter Bulletin Board
11. Generex to Participate in Canadian Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Inc. (NYSE: CRY ), a leading medical ... vascular surgery, announced today that James Patrick (Pat) ... elected to the Company,s Board of Directors, effective October ... Executive Chairman of CryoLife, stated, "Since joining the Company in ... who is well positioned to maximize CryoLife,s potential.  His ...
(Date:10/22/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... focused on the development of oral drug delivery ... its Phase IIa clinical trial of ORMD-0801, the ... 1 diabetes. The trial was conducted in ... Food and Drug Administration (FDA) Investigational New Drug ...
(Date:10/22/2014)... , Oct. 21, 2014  Early symptoms of ... or unnoticed, but new technology, coupled with yearly, ... leading to earlier detection of eye diseases, including ... million Americans. If left untreated, these diseases can ... Recently, optometric researchers have deployed ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately ... bacterial infections, microbial biofilms, and chronic wounds, announced that ... directors. , Dr. Sinskey is a ... Institute of Technology, or MIT. He has been a ... also holds positions as Co-Director of the Malaysia-MIT Biotechnology ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... undergoing in vitro fertilization (IVF) are only about half as ... assisted reproduction technique, new research indicates, and the racial disparity ... study, about 31 percent of white patients became pregnant after ... Analyzing more than 4,000 IVF cycles over two years to ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... may lead to increased blood pressure, according to a new ... in blood pressure for young adult women or for teenagers, ... drank lightly or moderately, their risk of high blood pressure ... parallels studies in older adult men and women," said lead ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... was diagnosed with Ebola while working for NBC News ... leave the special isolation unit at Nebraska Medical Center in Omaha, ... hospital said Tuesday. A blood test confirmed by the U.S. ... can head home to Providence, R.I., NBC News reported ...
Breaking Medicine News(10 mins):Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... will have the condition, experts say , , FRIDAY, Jan. 4 (HealthDay ... disability in the United States and now affects 46 million Americans, ... major new report finds. , That number is expected to rise ... percent of American adults will suffer from some form of arthritic ...
... for 29 categories of awards in the 2007 Association ... Best Monthly Professional Society Magazine as well as the ... winners will be honored at the Salute to Association ... 1996, JBS is the official publication of the Society ...
... 4 Align Technology,Inc. (Nasdaq: ALGN ), ... teeth without wires and brackets, announced today that ... end financial results on,Tuesday, January 29, 2008, after ... over PR Newswire and First Call and will ...
... CryoCor, Inc. (Nasdaq:,CRYO), a medical device company ... the publication of a European study of atrial,fibrillation ... of the study was to evaluate the role ... and the effectiveness of an ablation,strategy focused on ...
... El SEGUNDO, Calif., Jan. 4 DaVita Inc. ... Institute, PLC (,SKI,),have formed a wide-ranging partnership to ... chronic kidney disease education and research,in the greater ... SKI,s,existing dialysis centers and programs designed to provide ...
... COLUMBUS, Ohio, Jan. 2 Roxane Laboratories, ... New Drug Application (ANDA),for Granisetron Hydrochloride Tablets, ... The product is available in Unit Dose ... wholesalers and pharmacies nationwide., (Logo: ...
Cached Medicine News:Health News:46 Million Americans Suffer From Arthritis 2Health News:46 Million Americans Suffer From Arthritis 3Health News:Align Technology to Announce Fourth Quarter and 2007 Year End Financial Results on January 29, 2008 2Health News:Align Technology to Announce Fourth Quarter and 2007 Year End Financial Results on January 29, 2008 3Health News:CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation 2Health News:CryoCor Reports Publication in Circulation for Treatment of Atrial Fibrillation 3Health News:Roxane Laboratories, Inc. Announces the Launch of Granisetron Hydrochloride Tablets, 1mg 2
Epilation forceps straight ends size 3.5"....
Forceps, extra delicate, straight....
Jewelers Forceps, delicate, straight....
Jewelers Forceps, standard, straight....
Medicine Products: